Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-63.79%
0%
-63.79%
6 Months
-83.27%
0%
-83.27%
1 Year
-97.1%
0%
-97.1%
2 Years
-99.91%
0%
-99.91%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
Oxurion NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
13.88%
EBIT to Interest (avg)
-11.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.08
Tax Ratio
0.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
0
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-3.94
EV to EBITDA
-4.03
EV to Capital Employed
-9.27
EV to Sales
10.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-3.60
-13.50
73.33%
Interest
0.20
2.00
-90.00%
Exceptional Items
0.30
-5.10
105.88%
Consolidate Net Profit
0.10
-19.00
100.53%
Operating Profit Margin (Excl OI)
-1,239,666.70%
-52,190.10%
-1,18,747.66%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 100.53% vs 40.06% in Dec 2023
About Oxurion NV 
Oxurion NV
Pharmaceuticals & Biotechnology
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
Company Coordinates 
Company Details
Gaston Geenslaan 1 , HEVERLEE None : 3001
Registrar Details






